Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival.
Christopoulos P, Dietz S, Kirchner M, Volckmar AL, Endris V, Neumann O, Ogrodnik S, Heussel CP, Herth FJ, Eichhorn M, Meister M, Budczies J, Allgäuer M, Leichsenring J, Zemojtel T, Bischoff H, Schirmacher P, Thomas M, Sültmann H, Stenzinger A.
Christopoulos P, et al. Among authors: meister m.
Cancers (Basel). 2019 Jan 21;11(1):124. doi: 10.3390/cancers11010124.
Cancers (Basel). 2019.
PMID: 30669647
Free PMC article.